Biocon Limited
Biocon is engaged in the business of manufacture of biotechnology products and research services.(Source : 202003-01 Annual Report Page No:195)
What Biocon files
- Updates91
- Others75
- Important67
- Investor Meet62
- Board Meeting23
- PPTs9
Biocon's Q1 FY27 saw strong financial growth, with **Revenue from Operations rising 10% YoY to ₹4,336 Cr** and **Net Profit soaring 355% YoY to ₹141 Cr**. **Business Performance:** Biosimilars led the charge with **16% YoY growth to ₹2,855 Cr**, driven by North America. Generics also impressed, up **21% YoY to...
Here's a concise summary of Biocon's investor presentation: **Business Performance:** Biocon Group reported strong performance in FY26, with overall revenue reaching ₹16,927 Cr, a 10.9% year-over-year increase. Biosimilars were a key growth driver, surging 15.7% to ₹10,431 Cr and now account for 60% of total revenue. EBITDA stood at ₹3,798...
Biocon wrapped up FY26 with a strong performance, shifting from an investment phase to execution and value creation. Q4 revenue jumped 10% YoY (adjusted) to 4,517 Cr, with full-year revenue at 17,270 Cr, up 14% (adjusted). EBITDA also saw robust growth, rising 29% YoY (adjusted) in Q4 to 1,073 Cr...
Biocon Group's Q3FY26 revenue grew 9% YoY to ₹ 4,173 Cr, with net profit surging 475% YoY to ₹ 144 Cr. Generics revenue jumped 24% (₹ 851 Cr) from new GLP-1 launches. Biosimilars rose 9% (₹ 2,497 Cr), boosting segment EBITDA by 44% with strong North America traction. CRDMO dipped...
Here's a summary of Biocon Limited's Q3 FY26 earnings call: **Business Performance:** Biocon reported Q3 FY26 revenue from operations of ₹4,173 Cr, up 9% year-over-year (YoY). Biosimilars revenue grew 9% YoY to ₹2,497 Cr, driven by strong performance in North America, particularly oncology and immunology. Generics segment saw robust growth...